reports
XENOVIEW® 3T coil passes Philips compatibility testing
XENOVIEW® 3T coil passes Philips compatibility testing Polarean’s FDA cleared coil achieves important milestone, expanding clinical reach DURHAM, NC and LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces that its FDA-cleared XENOVIEW® 3T Chest Coil has successfully completed compatibility testing conducted by Philips (Philips Medical Systems Nederland B.V.) and is now confirmed for use with Philips’ latest 3T MRI platforms. Following extensive validat...
Korean distributor agreement with DK Healthcare in South Korea
Korean distributor agreement with DK Healthcare in South Korea Expanding commercial reach and advancing lung imaging innovation in Asia-Pacific DURHAM, NC and LONDON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces it has signed an exclusive distribution agreement with DK Healthcare Co., Ltd. (“DK Healthcare”) for the distribution of Polarean’s Xenon MRI platform in South Korea. This agreement represents Polare...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 24 November 2025
* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: On Friday 21st, Woodbois (WBI.L) left AIM. What’s baking in the oven? Potential** Initial Public Offerings:*** 24th Octobe...
- Colin Smith
Polarean Imaging | Proposed delisting from AIM market
Further to the strategic review announced on 22 October, Polarean has now formally proposed to delist from AIM and take the company private. The reasons cited by Polarean are: stronger access to capital, listing and compliance costs, public market undervaluation, and the current funding environment. Polarean reiterated its cash runway guidance through 2Q26 and its anticipated US$20m funding requirement. Cancellation from AIM is subject to a special resolution requiring a 75% vote in favour of th...
- Hybridan Team
- Jon Levinson
Friday Take Away: 10 October 2025
Friday Takeaway—delving a little deeper into UK small caps Friday Takeaway from UK Small Caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 10th October 2025 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication. Top three shareholders are taken from the webs...
- Hybridan Team
Hybridan Small Cap Feast: 06/10/2025
6th October 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: 6th October: Ashtead Technology (AT.L) announced it has moved from AIM to the Ma...
- Colin Smith
Polarean Imaging | Updates: NIH & UVA Health sales, Ascend expansion
Since the interim results, Polarean has made three further announcements including the sale of a complete Xenon MRI system to the National Institutes of Health Clinical Center, a significant follow on sale to the University of Virginia and, most recently, an expansion of the Representative Agreement it signed with Ascend Imaging (Ascend) in June. Collectively, we believe the new sales secure Polarean's current revenue guidance of US$2.5m-US$3.5m for 2025 and bode well for future sales announceme...
- Hybridan Team
- Jon Levinson
Friday Take Away: 26 September 2025
Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication. Top three shareholders are taken from the websites of the companies that we are writing about, unless there is a more up to date TR-1 notification RNS announcement. These companies require further funding in order to achieve their full potential from exciting market opportunities.
- Hybridan Team
Hybridan Small Cap Feast: 25/09/2025
25th September 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: None Delistings: None What’s baking in the oven? Potential** Init...
- Colin Smith
Polarean Imaging | 1H25 results – Tough half but robust pipeline
Polarean had a tough first half to June as disruption to US healthcare funding resulted in no additional sales of the company's Xenon MRI systems during the half, notwithstanding a 650% YoY increase in the sales pipeline. The weakness in capital sales was only partially mitigated by a 36% increase in consumables revenue. Cash and net cash ended the half at US$7.3m and the company reiterated its cash runway through 2Q26. Full year revenue guidance was reduced to US$2.5m-US$3.5m (from US$5m-US$6m)...
- Colin Smith
Polarean Imaging | Ascend representative agreement
Polarean has signed a Representative Agreement with Ascend Imaging LLC (Ascend) covering four specific US states. Under the agreement Ascend will act as a non-exclusive, independent manufacturer's representative supporting the promotion and sale of Polarean's Xenon MRI lung-imaging platform. Polarean has potential upside many times its current market capitalisation, we calculate, based on observable deal metrics and our NPV analysis, while the valuation is so low, it could attract take-over inte...
FDA expands XENOVIEW® indication to include children from six years of...
FDA expands XENOVIEW® indication to include children from six years of age Increases number of eligible patients by approximately one million DURHAM, NC and LONDON, June 02, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces that the US Food and Drug Administration (“FDA”) has approved the Company’s Supplemental New Drug Application (“NDA”) to expand the indication of XENOVIEW®. This approval immediately lowers the minimum pa...
- Colin Smith
Polarean Imaging | FDA extends use of XENOVIEW® to 6-year-olds
The US Food and Drug Administration (FDA) has approved Polarean's proven Xenon MRI platform for use in paediatric patients as young as six years old from the previous limit of 12. This approval increases the number of eligible patients by c1 million, confirming a total addressable market (TAM) in the US of cUS$2bn for use of the technology in evaluating ventilation. The FDA decision has come a little ahead of previous guidance. Approval for use in gas exchange, which remains subject to a clinica...
Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spect...
Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum 30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI DURHAM, NC and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, will be featured at the American Thoracic Society’s (ATS) 2025 Respiratory Innovation Summit (RIS), taking place May 16–17 at the Marriott Marquis in San Francisco, Californi...
- Hybridan Team
Hybridan Small Cap Feast: 08/05/2025
Claire Louise Noyce Managing Partner, Chief Executive Birchin Court, 20 Birchin Lane, London EC3V 9DU Tel direct: +44 (0)203 764 2341 Mobile: +44 (0)7894 267 530 Call me on teams E-mail: Whilst it suits me to email now, I do not expect any response outside your own work times. Linkedin: /in/claire-louise-noyce-25b4588a Website: Follow us on X @hybridanllp Follow us on Linkedin Hybridan LLP would love your feedback. Post ...
- Colin Smith
Polarean Imaging | FY24 results – sales growth guidance reiterated
Polarean has more than tripled revenue YoY to US$3.1m for the year to December 2024 and raised the gross margin by 841 basis points, confirming that it is on a path to hyperbolic growth. Almost more importantly, the cost of a Phase III trial for the use of its XENOVIEW® technology in gas exchange has been halved to US$4.0m-US$4.5m. The cash runway has been extended to 2Q26 and the company reiterated revenue guidance for 2025 of US$5.0m-US$6.0m. Polarean has potential upside many times its curren...
- Colin Smith
Polarean Imaging | Investor update presentation confirms thesis
Polarean held a presentation for investors to recap the investment thesis for its unique technology for visualising lung function and provide real life examples of its Xenon MRI imaging in both research and clinical use. Dr Alan Huang, recently appointed VP Global Sales, provided a positive update on the sales pipeline and process. Polarean reaffirmed existing guidance. However, while there was no new news, the presentation certainly helped demonstrate the enthusiasm with which Polarean's techno...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 10/03/2025
Our daily digest of news from UK Small Caps @HybridanLLP 10th March 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None W...
- Colin Smith
Polarean Imaging | Xenon MRI pharma research collaboration
Polarean has announced that its Xenon MRI lung imaging has been selected by a leading global pharma company to be included in a clinical trial due to start in 4Q25. This collaboration opens up a new vertical for Polarean but more importantly provides third party validation of the unmatched lung imaging that Polarean's Xenon MRI system provides. Polarean recently announced a better than expected update for FY24 which, in our view, confirms that the company is on the cusp of hyperbolic growth with...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 27/02/2025
Our daily digest of news from UK Small Caps @HybridanLLP 27th February 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: Delistings: What’s bak...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.